Cho WR, Wang CC, Tsai MJ, Lin CC, Yen YH, Chen CH, Kuo YH, Yao CC, Hung CH, Huang PY, Liu AC, Tsai MC*. Smoking as a Risk Factor for Very Late Recurrence in Surgically Resected Early-Stage Primary Hepatocellular Carcinoma. Clin Med Insights Oncol. 2024 Mar 5:18:11795549241228232. (SCI)
Lin YP, Tsai YC, Tsai MJ, Huang PY, Chen CH, Yao CC, Chuah SK, Kuo YH, Tai WC, Lian WS, Fang HW, Hu TH, Tsai MC*. Effect of gut microbiota and PNPLA3 polymorphisms on nonalcoholic fatty liver disease in lean and obese individuals. Adv Dig Med. 2023;1–11. DOI: 10.1002/aid2.13367
Tsai MC, Yong CC, Lin CC, Lee WC, Wang CC, Hung CH, Chen IH, Cheng YF, Hsiao CC*, Hu TH*, Chen CL. Living donor liver transplantation for Barcelona clinic liver cancer (BCLC) intermediate-stage hepatocellular carcinoma. HepatoBiliary Surg Nutr. 2023 Apr;12(2):169-182. (SCI)
Huang PY, Chen CH, Tsai MJ, Yao CC, Wang HM, Kuo YH, Chang KC, Hung CH, Chuah SK, Tsai MC*. Effects of direct anti-viral agents on the gut microbiota in patients with chronic hepatitis C. J Formos Med Assoc. 2023 Feb;122(2):157-163. (SCI)
Wang YC, Tsai MC(co-first), Chen YS(co-first), Hsieh PM, Hung CM, Lin HY, Hsu YC, Yeh JH, Hsiao PJ, Su YC, Ma CH, Lee CY, Lin CC, Shu CW , Li YC, Tsai MH, Yu Lin JY , Peng WH, Yu ML, Lin CW*. NPRL2 down-regulation facilitates the growth of hepatocellular carcinoma via the mTOR pathway and autophagy suppression. Hepatol Commun. 2022 Dec;6(12):3563-3577.
Tsai MC, Yang SS, Lin CC, Wang WL, Hsu YC, Chen YS, Hu JT, Lin JY, Yu ML, Lin CW*. Association of Heavy Alcohol Intake and ALDH2 rs671 Polymorphism With Hepatocellular Carcinoma and Mortality in Patients With Hepatitis B Virus-Related Cirrhosis. JAMA Netw Open. 2022 Jul 1;5(7):e2223511. (SCI)
Huang DS, Liu TT, Lu WT, Wang CC, Lin CC, Yong CC, Chen KD, Liu YW, Kuo YH, Yen YH, Hu TH, Tsai MC*. Comparison of portal and capsular microscopic vascular invasion in the outcomes of early HCC after curative resection. Am J Cancer Res. 2022 Jun 15;12(6):2659-2672. (SCI)
Chuang CH, Chen PC, Bai CH, Wu YL, Tsai MC*, Li CY. Association between Spinal Cord Injury and Alcohol Dependence: A Population-Based Retrospective Cohort Study. J Pers Med. 2022 Mar 16;12(3):473. (SCI)
Chen YS, Huang KH, Wang PM, Chuang CH, Yong CC, Liu YW, Huang PY, Yao CC, Lin YP, Tsai MC*. The Impact of Direct-Acting Antiviral Therapy on the Risk of Recurrence after Curative Resection in Patients with Hepatitis-C-Virus-Related Early Stage Hepatocellular Carcinoma. Medicina (Kaunas). 2022 Feb 9;58(2):259. (SCI)
Lin YP, Wang PM, Chuang CH, Yong CC, Liu YW, Huang PY, Yao CC, Tsai MC*. Metabolic Risks Are Increasing in Non-B Non-C Early-Stage Hepatocellular Carcinoma: A 10-Year Follow-Up Study. Front Oncol. 2022 Feb 2;12:816472. (SCI)
Tsai MC, Wang CC, Lee WC, Lin CC, Chang KC, Chen CH, Hung CH, Lin MT, Hsiao CC, Chen CL, Chien RN, Hu TH*. Tenofovir Is Superior to Entecavir on Tertiary Prevention for BCLC Stage 0/A Hepatocellular Carcinoma after Curative Resection. Liver Cancer. 2022 Jan;11:22–37. (SCI)
Tsai MC, Hung CH, Lu SN, Wang JH, Chen CH, Kee KM, Chang KC, Chao TL, Hu TH*. The incidence of resistance-associated variants to NS5A in HCV subtypes 1a and 1b in Taiwan. Biomed J. 2021 Dec;44(6S1):S126-S131. (SCI)
Chen YS#, Yang SY#, Wang PM, Wang CC, Yong CC, Chen DW, Liu YW, Chuang CH, Huang PY, Yao CC, Lin YP, Tsai MC*. Concurrent Cholecystectomy Is Associated with a Lower Risk of Recurrence after Curative Resection in Early-Stage Hepatocellular Carcinoma: A 10 Year Observational Single-Center Study. J Pers Med. 2021 Nov 30;11(12):1261.
Tsai YC, Sou FM, Liu YW, Wu YJ, Yong CC, Chen DW, Huang PY, Cho WR, Chuang CH, Hsiao CC, Hu TH, Tsai MC*. Preoperative ALBI grade predicts the outcomes in non-B non-C HCC patients undergoing primary curative resection. BMC Gastroenterol. 2021 Oct 19;21(1):386. (SCI)
Lin YP#, Lin SH#, Wang CC, Lin CC, Chen DW, Chuang CH, Huang PY, Hung CH, Yang SY, Cho WR, Chen YS, Tsai MC*. Impact of MAFLD on HBV-Related Stage 0/A Hepatocellular Carcinoma after Curative Resection. J Pers Med. 2021 Jul 21;11(8):684. (SCI)
Tsai MC, Lin CC, Chen DW, Liu YW, Wu YJ, Yen YH, Huang PY, Yao CC, Chuang CH, Hsiao CC*. The Role of Protease-Activated Receptor 2 in Hepatocellular Carcinoma after Hepatectomy. Medicina (Kaunas). 2021 Jun 4;57(6):574. (SCI)
Cho WR, Wang CC, Tsai MY, Chou CK, Liu YW, Wu YJ, Lin MT, Chen KD, Chuang CH, Huang PY, Hu TH, Tsai MC*. Impact of metformin use on the recurrence of hepatocellular carcinoma after initial liver resection in diabetic patients. PLoS One. 2021 Mar 4;16(3):e0247231. (SCI)
Yang SY, Wang CC, Chen KD, Liu YW, Lin CC, Chuang CH, Tsai YC, Yao CC, Yen YH, Hsiao CC, Hu TH, Tsai MC*. Statin use is associated with a lower risk of recurrence after curative resection in BCLC stage 0-A hepatocellular carcinoma. BMC Cancer. 2021 Jan 15;21(1):70. (SCI)
Tsai MC, Chang KC, Yen YH, Wu CK, Lin MT, Hu TH*.Comparison of tenofovir and entecavir in the development of acute kidney injury in cirrhotic chronic hepatitis B patients with refractory ascites.
Eur J Gastroenterol Hepatol. 2021 Feb 1;32(2):208-213. (SCI)
Cho WR, Hung CH, Chen CH, Lin CC, Wang CC, Liu YW, Wu YJ, Yong CC, Chen KD, Tsai YC, Hu TH, Tsai MC*. Ability of the post-operative ALBI grade to predict the outcomes of hepatocellular carcinoma after curative surgery. Sci Rep. 2020 Apr 29;10(1):7290. (SCI)
Tsai MC*, Liu YY, Lin CC, Wang CC, Wu YJ, Yong CC, Chen KD, Chuah SK, Yao CC, Huang PY, Chen CH, Hu TH, Chen CL. Gut Microbiota Dysbiosis in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study in Taiwan. Nutrients. 2020 Mar 19;12(3):820. (SCI)
Tsai MC, Huang CC, Wei YC, Liu TT, Lin MT, Yi LN, Lin PR, Wang CC, Chu TH, Hsiao CC, Hu TH*, Tai MH*. Combined Chibby and β-Catenin Predicts Clinical Outcomes in Patients with Hepatocellular Carcinoma. Int J Mol Sci. 2020 Mar 17;21(6):2060. (SCI)
Lin CY, Lin CC, Wang CC, Chen CL, Hu TH, Hung CH, Huang PY, Tsai MC*. The ALBI Grade is a Good Predictive Model for Very Late Recurrence in Patients with Hepatocellular Carcinoma Undergoing Primary Resection. World J Surg. 2020 Jan;44(1):247-257. (SCI)
Tsai MC, Yen YH, Chang KC, Hung CH, Chen CH, Lin MT, Hu TH*. Elevated levels of serum urokinase plasminogen activator predict poor prognosis in hepatocellular carcinoma after resection. BMC Cancer. 2019 Dec 2;19(1):1169. (SCI)
Tsai MY, Yen YH, Huang PY, Sou FM, Lin CC, Cho WR, Wang HM, Chen DW, Chang KC, Wu CK, Hu TH, Tsai MC*. The Pre- and Postoperative FIB-4 Indexes Are Good Predictors to the Outcomes of HBV-Related HCC Patients after Resection. Gastroenterol Res Pract. 2019 Dec 1;2019:8945798. (SCI)
Tsai MC#, Lin CY#, Hung CH, Lu SN, Tung SY, Chien RN, Lin CL, Wang JH, Chen CH, Chang KC, Hu TH*, Sheen IS*. Evolution of renal function under direct-acting antivirals treatment for chronic hepatitis C: A real-world experience. J Viral Hepat. 2019 Dec;26(12):1404-1412. (SCI)
Huang PY, Wang CC, Lin CC, Lu SN, Wang JH, Hung CH, Kee KM, Chen CH, Chen KD, Hu TH, Tsai MC*. Predictive Effects of Inflammatory Scores in Patients with BCLC 0-A Hepatocellular Carcinoma after Hepatectomy. J Clin Med. 2019 Oct 14;8(10):1676. (SCI)
Tsai MC, Chen CH, Hu TH, Lu SN, Lee CM, Wang JH, Hung CH*.Long-term outcomes of hepatitis B virus-related cirrhosis treated with nucleos(t)ide analogs. J Formos Med Assoc. 2017 July; 116(7)512-521. (SCI)
Tsai MC, Chen CH, Tseng PL, Hung CH, Chiu KW, Chang KC, Yen YH, Lin MT, Hu TH*. Does Nucleos(t)ide Analogues Treatment Affect Renal Function in Chronic Hepatitis B Patients Who Have Already Decreased eGFR? A Longitudinal Study. PLoS One. 2016 Mar 10;11(3):e0149761. (SCI)
Tsai MC, Chen CH, Tseng PL, Hung CH, Chiu KW, Wang JH, Lu SN, Lee CM, Chang KC, Yen YH, Lin MT, Chou YP, Hu TH*. Comparison of renal safety and efficacy of telbivudine, entecavir and tenofovir treatment in chronic hepatitis B patients: real world experience. Clin Microbiol Infect. 2016 Jan;22(1):95.e1-7. (SCI)
Tsai MC, Yu HC(co-first), Hung CH, Lee CM, Chiu KW, Lin MT, Tseng PL, Chang KC, Yen YH, Chen CH*, Hu TH*. Comparing the efficacy and clinical outcome of telbivudine and entecavir naive patients with hepatitis B virus-related compensated cirrhosis. J Gastroenterol Hepatol. 2014 Mar;29(3):568-75. (SCI)
Tsai MC, Chen CH*, Hung CH, Lee CM, Chiu KW, Wang JH, Lu SN, Tseng PL, Chang KC, Yen YH, Hu TH*. A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B: a match-control study. Clin Microbiol Infect. 2014 Feb;20(2):090-0100. (SCI)
Tsai MC, Lee CM, Chiu KW, Hung CH, Tung WC, Chen CH, Tseng PL, Chang KC, Wang JH, Lu SN, Yen YH, Hu TH*. A comparison of telbivudine and entecavir for chronic hepatitis B in real-world clinical practice. J Antimicrob Chemother. 2012 Mar;67(3):696-9. (SCI)
Tsai MC, Chen YT, Chien YS, Chen TC, Hu TH*. Hepatitis B virus infection and renal transplantation. World J Gastroenterol. 2010 Aug 21;16(31):3878-87. Review. (SCI)
Tsai MC, Wang JH, Hung CH, Kee KM, Yen YH, Lee CM, Hu TH, Chen CH, Lu SN*. Favorable alpha-fetoprotein decrease as a prognostic surrogate in patients with hepatocellular carcinoma after radiofrequency ablation. J Gastroenterol Hepatol. 2010 Mar;25(3):605-12. (SCI)
Tsai MC, Lin MC, Hung CH*. Successful antiviral and antituberculosis treatment with pegylated interferon-alfa and ribavirin in a chronic hepatitis C patient with pulmonary tuberculosis. J Formos Med Assoc. 2009 Sep;108(9):746-50. (SCI)
Tsai MC, Chen CH, Lee CM, Chen YT, Chien YS, Hung CH, Wang JH, Lu SN, Yen YH, Changchien CS, Hu TH*. The role of HBV genotype, core promoter and precore mutations in advanced liver disease in renal transplant recipients. J Hepatol. 2009 Feb;50(2):281-8. (SCI)
Tsai MC, Lin JW, Lin SE, Chen HH, Lee CM, Hu TH*. Prognostic analysis of rectal stromal tumors by reference of National Institutes of Health risk categories and immunohistochemical studies. Dis Colon Rectum. 2008 Oct;51(10):1535-43. (SCI)
